Pharsight

Drugs that contain Zoledronic Acid

1. Reclast patents expiration

RECLAST's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US4939130 SANDOZ Substituted alkanediphosphonic acids and pharmaceutical use
Sep, 2012

(11 years ago)

US4939130

(Pediatric)

SANDOZ Substituted alkanediphosphonic acids and pharmaceutical use
Mar, 2013

(11 years ago)

US8052987 SANDOZ Method of administering bisphosphonates
Oct, 2023

(7 months ago)

US7932241 SANDOZ Pharmaceutical products comprising bisphosphonates
Feb, 2028

(3 years from now)

US7932241

(Pediatric)

SANDOZ Pharmaceutical products comprising bisphosphonates
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-595) May 29, 2012
New Indication(I-581) Dec 19, 2011
New Indication(I-584) Mar 15, 2012

Market Authorisation Date: 16 April, 2007

Treatment: Treatment of osteoporosis in postmenopausal women; Treatment and prevention of postmenopausal or glucocorticoid-induced osteoporosis and treatment to increase bone mass in men with osteoporosis

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of RECLAST before it's drug patent expiration?
More Information on Dosage

RECLAST family patents

Family Patents

2. Zometa patents expiration

ZOMETA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US4939130 NOVARTIS Substituted alkanediphosphonic acids and pharmaceutical use
Sep, 2012

(11 years ago)

US4939130

(Pediatric)

NOVARTIS Substituted alkanediphosphonic acids and pharmaceutical use
Mar, 2013

(11 years ago)

US8324189 NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
May, 2025

(11 months from now)

US8324189

(Pediatric)

NOVARTIS Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
Nov, 2025

(1 year, 5 months from now)

US7932241 NOVARTIS Pharmaceutical products comprising bisphosphonates
Feb, 2028

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Sep 20, 2011

Market Authorisation Date: 20 August, 2001

Treatment: Hypercalcemia of malignancy

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ZOMETA before it's drug patent expiration?
More Information on Dosage

ZOMETA family patents

Family Patents